Evidence map›Paper›PMID 29511455›Full record

ArticleAmerican journal of translational research2018

Interplay between long noncoding RNA ZEB1-AS1 and miR-101/ZEB1 axis regulates proliferation and migration of colorectal cancer cells.

Wan-Cheng Xiong, Na Han, Nan Wu, Ke-Lei Zhao, Chen Han, Hui-Xin Wang, Guan-Fang Ping, Peng-Fei Zheng, Hailong Feng, Lei Qin and 1 more

Open access · greenAbstract read
In one paragraph

Article in American journal of translational research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
3.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 63 citations in OpenAlex.

  1. Review
  2. Disulfidptosis in tumor progression.Cell death discovery · 2025
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Wan-Cheng XiongDepartment of General Surgery, First Affiliated Hospital of Xinxiang Medical UniversityWeihui 453100, Henan, China.
Na HanDepartment of Central Laboratory, First Affiliated Hospital of Xinxiang Medical UniversityWeihui 453100, Henan, China.
Nan WuDepartment of Pharmacy, First Affiliated Hospital of Xinxiang Medical UniversityWeihui 453100, Henan, China.
Ke-Lei ZhaoDepartment of Oncology, First Affiliated Hospital of Xinxiang Medical UniversityWeihui 453100, Henan, China.
Chen HanDepartment of Pharmacy, First Affiliated Hospital of Xinxiang Medical UniversityWeihui 453100, Henan, China.
Hui-Xin WangDepartment of Pharmacy, First Affiliated Hospital of Xinxiang Medical UniversityWeihui 453100, Henan, China.
Guan-Fang PingDepartment of Pharmacy, First Affiliated Hospital of Xinxiang Medical UniversityWeihui 453100, Henan, China.
Peng-Fei ZhengDepartment of General Surgery, First Affiliated Hospital of Xinxiang Medical UniversityWeihui 453100, Henan, China.
Hailong FengDepartment of General Surgery, First Affiliated Hospital of Xinxiang Medical UniversityWeihui 453100, Henan, China.
Lei QinDepartment of Gastroenterology, First Affiliated Hospital of Xinxiang Medical UniversityWeihui 453100, Henan, China.
Peng HeDepartment of General Surgery, First Affiliated Hospital of Xinxiang Medical UniversityWeihui 453100, Henan, China.
First Affiliated Hospital of Xinxiang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long noncoding RNAs (lncRNAs) are dysregulated in many diseases. MicroRNA-101 (miR-101) functions as a tumor suppressor by directly targeting ZEB1 in various cancers. However, the potential mechanism of lncRNA ZEB1-AS1 and miR-101/ZEB1 axis in CRC remains unknown. In this study, we further investigated the potential interplay between miR-101/ZEB1 axis and lncRNA ZEB1-AS1 in colorectal cancer (CRC). Results showed that ZEB1-AS1 was upregulated in CRC tissues and cells. MiR-101 was downregulated in CRC tissues and negatively correlated with ZEB1-AS1 and ZEB1 expression levels in CRC. Functional experiments showed that, consistent with ZEB1-AS1 depletion, miR-101 overexpression and ZEB1 depletion inhibited the proliferation and migration of CRC cells. Overexpression of miR-101 partially abolished the effects of ZEB1-AS1 on the proliferation and migration of these cells. Moreover, combined ZEB1-AS1 depletion and miR-101 overexpression significantly inhibited cell proliferation and migration of the CRC cells. Hence, ZEB1-AS1 functioned as a molecular sponge for miR-101 and relieved the inhibition of ZEB1 caused by miR-101. This study revealed a novel regulatory mechanism between ZEB1-AS1 and miR-101/ZEB1 axis. The interplay between ZEB1-AS1 and miR-101/ZEB1 axis contributed to the proliferation and migration of CRC cells, and targeting this interplay could be a promising strategy for CRC treatment.

Indexed as

lncRNA ZEB1-AS1migrationmiR-101proliferationZEB1

Identifiers

PMID29511455
PMCPMC5835826
OpenAlexW2981291069

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.